Tesamorelin
10mg
Tesamorelin is the only compound in this catalog with completed Phase 3 trial data. It selectively reduces visceral adipose tissue, the metabolically active fat surrounding internal organs, by an average 18% in controlled trials while preserving lean muscle mass.
Included free with every order
Bacteriostatic reconstitution solution and sterile dosing needles are included, a $30+ value, always included. Most suppliers charge extra. We never do.
Purity
99.2%
Form
Lyophilized powder
Storage
-20°C
Includes
Solution + needles
Research use only. Not for human consumption. Need help reconstituting? Use our dosing calculator.
Research Outcomes
What The Clinical Data Shows
Based on published peer-reviewed literature. Not medical claims.
18%
Visceral adipose tissue reduction in Phase 3 trials
Phase 3
The only peptide in this catalog with completed Phase 3 data
26%
Improvement in cognitive function scores, secondary analysis
Fat depot selectivity. MRI confirmed an 18% reduction in visceral fat versus just 3% in subcutaneous fat, showing high depot selectivity.
Cognitive outcome. Subjects with mild cognitive impairment showed a 26% improvement in executive function, attributed to IGF-1's neuroprotective effects and reduced inflammatory burden.
IGF-1 normalization. Restored IGF-1 to young-adult reference ranges in 78% of subjects over 50, with corresponding gains in lean mass and bone density.
Lipid profile. Triglycerides fell by more than 50 mg/dL on average, with HDL increases and reduced liver fat exceeding what fat loss alone would predict.
Research context. All findings are from peer-reviewed literature. Not FDA-approved. Sold for research purposes only. Results in research settings may vary. Not medical advice.